Journal article
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype
Breast cancer research : BCR, Vol.15(4), pp.R68-R68
2013
DOI: 10.1186/bcr3462
PMCID: PMC3978610
PMID: 23971947
Abstract
Introduction
Estrogen receptor (ER) and progesterone receptor (PR) testing are performed in the evaluation of breast cancer. While the clinical utility of ER as a predictive biomarker to identify patients likely to benefit from hormonal therapy is well-established, the added value of PR is less well-defined. The primary goals of our study were to assess the distribution, inter-assay reproducibility, and prognostic significance of breast cancer subtypes defined by patterns of ER and PR expression.
Methods
We integrated gene expression microarray (GEM) and clinico-pathologic data from 20 published studies to determine the frequency (n = 4,111) and inter-assay reproducibility (n = 1,752) of ER/PR subtypes (ER+/PR+, ER+/PR-, ER-/PR-, ER-/PR+). To extend our findings, we utilized a cohort of patients from the Nurses’ Health Study (NHS) with ER/PR data recorded in the medical record and assessed on tissue microarrays (n = 2,011). In both datasets, we assessed the association of ER and PR expression with survival.
Results
In a genome-wide analysis, progesterone receptor was among the least variable genes in ER- breast cancer. The ER-/PR+ subtype was rare (approximately 1 to 4%) and showed no significant reproducibility (Kappa = 0.02 and 0.06, in the GEM and NHS datasets, respectively). The vast majority of patients classified as ER-/PR+ in the medical record (97% and 94%, in the GEM and NHS datasets) were re-classified by a second method. In the GEM dataset (n = 2,731), progesterone receptor mRNA expression was associated with prognosis in ER+ breast cancer (adjusted P <0.001), but not in ER- breast cancer (adjusted P = 0.21). PR protein expression did not contribute significant prognostic information to multivariate models considering ER and other standard clinico-pathologic features in the GEM or NHS datasets.
Conclusion
ER-/PR+ breast cancer is not a reproducible subtype. PR expression is not associated with prognosis in ER- breast cancer, and PR does not contribute significant independent prognostic information to multivariate models considering ER and other standard clinico-pathologic factors. Given that PR provides no clinically actionable information in ER+ breast cancer, these findings question the utility of routine PR testing in breast cancer.
Details
- Title: Subtitle
- Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype
- Creators
- Marco M Hefti - Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USARong Hu - Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USANicholas W Knoblauch - Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USALaura C Collins - Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USABenjamin Haibe-Kains - Integrative Systems Biology, Institut de Recherches Cliniques de Montréal, University of Montreal, Montreal, QC, CanadaRulla M Tamimi - Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAAndrew H Beck - Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
- Resource Type
- Journal article
- Publication Details
- Breast cancer research : BCR, Vol.15(4), pp.R68-R68
- DOI
- 10.1186/bcr3462
- PMID
- 23971947
- PMCID
- PMC3978610
- NLM abbreviation
- Breast Cancer Res
- ISSN
- 1465-5411
- eISSN
- 1465-542X
- Publisher
- BioMed Central
- Language
- English
- Date published
- 2013
- Academic Unit
- Pathology; Iowa Neuroscience Institute
- Record Identifier
- 9984047692002771
Metrics
20 Record Views